Investor Presentaiton
Pharma Segment Core Therapeutic Area Revenue
1H22 Core Therapeutic Area Revenue
Cardiovasc
ular
system
Central
nervous
system
4%
11%
API and Intermediates
7%
Metabolis
m and
alimentary
system
14%
Anti-tumor
and
immune
modulation
(RMB million)
49.56% YoY
36.63% YoY
3,629
2,550
2,656
1,705
-2.54% YoY
7.46% YoY
1,419 1,383
1,019 1,095
-31.49% YoY
616
422
Anti-
infection
38%
26%
Anti-tumor and
immune modulation
Anti-infection
Metabolism and
alimentary system
Cardiovascular
system
Central nervous
system
1H21 1H22
17
•
•.
•
•
Anti-tumor and immune modulation core products: increase was mainly due to the revenue increase from Han Qu You (Trastuzumab
Injection), Han Li Kang (Rituximab Injection), and Su Ke Xin (Avatrombopagmaleate Tablets) and the revenue from new launches including
Han Si Zhuang (Serplulimab Injection) and Akynzeo (Netupitant-Palonosetron)
Anti-infection core products: increase was mainly due to the sales contribution from mRNA COVID-19 vaccine and the sales revenue
increase of anti-malarial products (Artesunate)
Metabolism and alimentary system core products: decrease was mainly due to the decrease in sales volume and unit price of Atomolan
(glutathione for injection) and Fan Ke Jia (thioctic acid injection) after the volume-based purchasing
Cardiovascular system core products: increase was mainly due to the revenue increase from heparin series preparations
Central nervous system core products: decrease was mainly due to the sales decline of Ao De Jin (Deproteinized Calf Blood Injection)
Note: 1H21 revenue is restated by including new core product Wan Su Jing (Engeletin Tablets) and excluding Shi Li Da (amlodipine besylate tablets) from disposed Huanghe Pharma in 1H22View entire presentation